title: Chymase inhibitor, BCEAB, suppressed peritoneal adhesion formation in hamster.
abstract: BACKGROUND
  Mast cells are closely related to adhesion formation, while it has been unclear which factor in mast cells plays an important role in the development of adhesion formation. To clarify the role of chymase produced from mast cells in adhesion formation, we investigated the preventive effect of a specific chymase inhibitor, BCEAB, on adhesion formation in a hamster experimental model.
  
  
  METHODS
  Hamsters were administered orally once daily with 100 mg/kg of BCEAB or placebo from the operated day to 1 week after the operation. The uterus was grasped and denuded by a swab.
  
  
  RESULTS
  One week after the operation, the scores for adhesion formation in the chymase inhibitor-treated group were significantly decreased in comparison with those in the placebo-treated group (placebo-treated group, 2.80 +/- 0.20; chymase inhibitor-treated group 1.60 +/- 0.31: P < 0.01). The chymase activity in the injured uterus was also significantly suppressed in the chymase inhibitor-treated group (placebo-treated group, 17.3 +/- 2.69 mU/mg protein; chymase inhibitor-treated group 9.60 +/- 0.89: P < 0.05). After scraping the utelus, the level of transforming growth factor-beta in the peritoneal fluid was significantly increased in the placebo-treated group, while it was suppressed to 70% by the treatment with BCEAB.
  
  
  CONCLUSIONS
  The specific chymase inhibitor BCEAB may be a useful drug for prevention of adhesion formation.
authors.affiliation: Department of Pharmacology, Osaka Medical College, Takatsuki City, Japan.
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Shinji
authors.initials: S
authors.lastname: Takai
authors.forename: Mizuo
authors.initials: M
authors.lastname: Miyazaki
mesh_terms: D000818:Animals; D001384:Azetidines / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D053818:Chymases; D006224:Cricetinae; D005260:Female; D008647:Mesocricetus; D010532:Peritoneal Diseases / Q000517:prevention & control*; D012697:Serine Endopeptidases / Q000187:drug effects* / Q000502:physiology; D000267:Tissue Adhesions / Q000517:prevention & control*; D016212:Transforming Growth Factor beta / Q000032:analysis
chemical_list: C439760:4-(1-((bis(4-methylphenyl)methyl)carbamoyl)-3-(2-ethoxybenzyl)-4-oxoazetidine-2-yloxy)benzoic acid; D001384:Azetidines; D001565:Benzoates; D016212:Transforming Growth Factor beta; D012697:Serine Endopeptidases; D053818:Chymases